NSE filing, NSE: QLINE. Summary written from the filing by ALFA Finder's alert engine.
Q-Line Biotech Ltd: key numbers
- Share price
- ₹544.45
- Market cap
- ₹1,270 Cr
- Revenue (annual)
- ₹341.7 Cr
- Net profit (annual)
- ₹55.72 Cr
- P/E (TTM)
- 22.8×Sector 52.0×
- Promoter holding
- 67.51%
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Q-Line Biotech Ltd
All →Q-Line Biotech Annual General Meeting
Q-Line Biotech Limited held its 16th Annual General Meeting on September 30, 2026. The meeting transacted ordinary and special business, including financial statement adoption and director re-appointments.
Q-Line Biotech Annual General Meeting
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.
Q-Line Biotech Annual Report
Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26. The full document is accessible via the provided company website link.
Q-Line Biotech Other Announcement
Q-Line Biotech Limited has re-appointed M/s. P S P & Associates as Cost Auditors for a 12-month term.
- Execution
- 12 months
Q-Line Biotech Partnership
Q-Line Biotech amended its license agreement with Boule Medical AB, Sweden. The revision includes a 25% reduction in license/royalty costs effective from July 2026.
- From
- Boule Medical AB
- Execution
- 5 years
Q-Line Biotech Other Announcement
Q-Line Biotech Limited filed its quarterly Reconciliation of Share Capital Audit Report, as required under SEBI Regulation 76, for the quarter ended June 30, 2026.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.